SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

	UNDER THE SECURITIES EXCHANGE ACT OF 1934
	(Amendment No. 1)*
	Dermata Therapeutics, Inc.
	(Name of Issuer)
	Common stock, par value \$0.0001 per share
	(Title of Class of Securities)
	249845405
	(CUSIP Number)
	03/31/2025
	(Date of Event Which Requires Filing of this Statement)
Check th	e appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule	13d-1(b)
Rule	13d-1(c)
Rule	13d-1(d)
	SCHEDULE 13G
CUSIP N	No. 249845405
1	Names of Reporting Persons Mitchell P. Kopin
2	Check the appropriate box if a member of a Group (see instructions) (a) (b)
3	Sec Use Only
4	Citizenship or Place of Organization

UNITED STATES

Number of Shares Benefici ally Owned by Each Reporti ng Person	5	Sole Voting Power	
	J	0.00	
	6	Shared Voting Power	
	6	23,340.00	
	7	Sole Dispositive Power	
	,	0.00	
With:	8	Shared Dispositive Power	
	0	23,340.00	
	Aggregate Amount Beneficially Owned by Each Reporting Person		
9	23,340.00		
40	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)		
10			
44	Percent of class represented by amount in row (9)		
11	0.4 %		
42	Type of Reporting Person (See Instructions)		
12	HC, IN		

SCHEDULE 13G

|--|--|--|--|--|--|

1	Names of Reporting Persons			
Ĭ.	Daniel B. Asher			
	Check the appropriate box if a member of a Group (see instructions)			
2	(a) (b)			
3	Sec Use Only			
4	Citizenshi	ip or Place of Organization		
-	UNITED S	UNITED STATES		
		Sole Voting Power		
Number	5	0.00		
of Shares		Shared Voting Power		
Benefici ally Owned	6	23,340.00		
by Each Reporti	7	Sole Dispositive Power		
ng Person		0.00		
With:	8	Shared Dispositive Power		
		23,340.00		
	Aggregate Amount Beneficially Owned by Each Reporting Person			
9	23,340.00			
40	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)			
10				
	-			

11	Percent of class represented by amount in row (9)
''	0.4 %
40	Type of Reporting Person (See Instructions)
12	HC, IN

SCHEDULE 13G

CUSIP No.	249845405		
-----------	-----------	--	--

1	Names of Reporting Persons				
,	Intracoastal Capital LLC				
	Check the appropriate box if a member of a Group (see instructions)				
2	(a) (b)				
3	Sec Use Only				
4	Citizensh	Citizenship or Place of Organization			
7	DELAWAF	DELAWARE			
	_	Sole Voting Power			
Number	5	0.00			
of Shares Benefici	6	Shared Voting Power			
ally Owned		23,340.00			
by Each Reporti	7	Sole Dispositive Power			
ng Person		0.00			
With:	8	Shared Dispositive Power			
		23,340.00			
	Aggregate Amount Beneficially Owned by Each Reporting Person				
9	23,340.00				
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)				
10					
	Parasant of class represented by amount in your (0)				
11	Percent of class represented by amount in row (9) 0.4 %				
		Departing Parson (See Instructions)			
12	Type of Reporting Person (See Instructions)				
1	00				

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Dermata Therapeutics, Inc.

(b) Address of issuer's principal executive offices:

3525 Del Mar Heights Rd., #322, San Diego, CA 92130

Item 2.

(a) Name of person filing:

This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").

(b) Address or principal business office or, if none, residence:

The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

(c) Citizenship:

Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.

(d) Title of class of securities:

Common stock, par value \$0.0001 per share

(e) CUSIP No.:

249845405

Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	■ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	■ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	■ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)		An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
-----	--	--	----

- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) Amount beneficially owned:

As of the close of business on March 31, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 23,340 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 1"), and all such shares of Common Stock represent beneficial ownership of approximately 0.4% of the Common Stock, based on (1) 5,430,648 shares of Common Stock outstanding as of March 11, 2025, as reported by the Issuer, plus (2) 23,340 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes 262,468 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal ("Intracoastal Warrant 2") because Intracoastal Warrant 2 is not exercisable until the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 (and Intracoastal Warrant 2 also contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock). Without such blocker provision (and assuming Intracoastal Warrant 2 was currently exercisable), each of the Reporting Persons may have been deemed to have beneficial ownership of 285,808 shares of Common Stock.

(b) Percent of class:

0.4 %

- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote:

(ii) Shared power to vote or to direct the vote:

23,340

(iii) Sole power to dispose or to direct the disposition of:

0

(iv) Shared power to dispose or to direct the disposition of:

23,340

- Item 5. Ownership of 5 Percent or Less of a Class.
 - Ownership of 5 percent or less of a class
- Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mitchell P. Kopin

Signature: /s/ Mitchell P. Kopin
Name/Title: Mitchell P. Kopin
Date: 05/09/2025

Daniel B. Asher

Signature: /s/ Daniel B. Asher
Name/Title: Daniel B. Asher
Date: 05/09/2025

Intracoastal Capital LLC

Signature: /s/ Mitchell P. Kopin
Name/Title: Mitchell P. Kopin, Manager

Date: 05/09/2025